Key Takeaways
- • Sycamore Partners is in advanced discussions to sell Boots to the Canadian Weston family through its investment vehicle Wittington Investments for approximately $9 billion, with a deal potentially closing within weeks.
- • The acquisition would be executed through Wittington Investments, which already owns Canadian grocery retailer Loblaws and pharmacy chain Shoppers Drug Mart, expanding the Weston family's international retail footprint.
- • Boots generated £7.5 billion in revenue for the year to August 2025 (up 3.2%) with pre-tax profit of £337 million (up approximately 25%), demonstrating operational strength ahead of the potential sale.
- • Sycamore acquired Boots in 2024 as part of its $23.7 billion takeover of Walgreens Boots Alliance, with the Pessina family retaining a 44% stake in the separated entity.
- • The potential transaction marks the Weston family's return to UK retail investment four years after selling Selfridges for £4 billion, while the British arm of the family already controls Primark owner Associated British Foods and luxury retailer Fortnum & Mason.
Summary
Sycamore Partners has entered advanced negotiations to divest Boots, the UK health and beauty retailer, to the Canadian branch of the billionaire Weston family in a transaction valued at approximately $9 billion. According to the Financial Times, deal discussions have progressed to a stage where an agreement could be reached within days, though negotiations remain fluid and terms remain subject to change.
The Weston family would acquire Boots through Wittington Investments, its primary investment vehicle, which currently operates Canadian grocery chain Loblaws and pharmacy operator Shoppers Drug Mart. This transaction would provide the family with a significant re-entry point into UK retail markets, following its divestment of the Selfridges department store for £4 billion four years prior. The family's existing UK retail presence includes control of Primark through parent company Associated British Foods and ownership of luxury retailer Fortnum & Mason.
Sycamore acquired Boots in 2024 as part of its larger $23.7 billion takeover of Walgreens Boots Alliance. Following the acquisition, Sycamore executed a separation of the combined entity into five standalone businesses, with Boots as a distinct operating unit. Notably, Stefano Pessina's family retained a 44% stake across each of the separated companies, preserving significant ongoing exposure to Boots' performance.
Boots has demonstrated solid operational performance, which likely strengthens Sycamore's negotiating position. For the financial year ending August 2025, the retailer reported revenue of £7.5 billion, representing 3.2% year-over-year growth, while pre-tax profit surged to £337 million—approximately 25% higher than the prior year. Management attributed the profit growth partly to the reversal of impairment charges and partly to strong performance from newer beauty brands and increased demand for weight-loss treatment products.
The Boots sale process extends back to 2022, when Walgreens first initiated strategic review discussions. Prior to Sycamore's acquisition and the current negotiations with the Weston family, the company had also held discussions with Australian pharmacy operator Sigma Healthcare. Previous bids from private capital investors failed to meet seller valuation expectations, indicating that the $9 billion price point represents a significant achievement in resolving a multi-year exit process.
The Weston family would acquire Boots through Wittington Investments, its primary investment vehicle, which currently operates Canadian grocery chain Loblaws and pharmacy operator Shoppers Drug Mart. This transaction would provide the family with a significant re-entry point into UK retail markets, following its divestment of the Selfridges department store for £4 billion four years prior. The family's existing UK retail presence includes control of Primark through parent company Associated British Foods and ownership of luxury retailer Fortnum & Mason.
Sycamore acquired Boots in 2024 as part of its larger $23.7 billion takeover of Walgreens Boots Alliance. Following the acquisition, Sycamore executed a separation of the combined entity into five standalone businesses, with Boots as a distinct operating unit. Notably, Stefano Pessina's family retained a 44% stake across each of the separated companies, preserving significant ongoing exposure to Boots' performance.
Boots has demonstrated solid operational performance, which likely strengthens Sycamore's negotiating position. For the financial year ending August 2025, the retailer reported revenue of £7.5 billion, representing 3.2% year-over-year growth, while pre-tax profit surged to £337 million—approximately 25% higher than the prior year. Management attributed the profit growth partly to the reversal of impairment charges and partly to strong performance from newer beauty brands and increased demand for weight-loss treatment products.
The Boots sale process extends back to 2022, when Walgreens first initiated strategic review discussions. Prior to Sycamore's acquisition and the current negotiations with the Weston family, the company had also held discussions with Australian pharmacy operator Sigma Healthcare. Previous bids from private capital investors failed to meet seller valuation expectations, indicating that the $9 billion price point represents a significant achievement in resolving a multi-year exit process.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.